AVTE Aerovate Therapeutics, Inc.

Nasdaq aerovatetx.com


$ 9.61 $ -0.38 (-3.79 %)    

Wednesday, 22-Oct-2025 15:59:59 EDT
QQQ $ 605.50 $ -5.89 (-0.96 %)
DIA $ 465.12 $ -3.44 (-0.73 %)
SPY $ 667.77 $ -3.49 (-0.52 %)
TLT $ 92.19 $ 0.06 (0.07 %)
GLD $ 376.54 $ 0.04 (0.01 %)
$ 9.65
$ 10.02
$ 8.55 x 100
$ 10.40 x 130
$ 9.30 - $ 10.16
$ 6.57 - $ 13.50
213,763
na
314.85M
$ 0.84
nm
TBD
na
na ($ 0.25)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 04-25-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-25-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aerovate-therapeutics-stockholders-approve-proposed-merger-with-jade-biosciences-board-approves-1-for-35-reverse-stock-split

—Aerovate Board of Directors approves 1-for-35 reverse stock split—WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Ther...

 aerovate-therapeutics-declares-special-cash-dividend-of-696m-or-an-estimated-240-per-share

Aggregate cash dividend of $69.6 million, or an estimated $2.40 per shareWALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate...

 aerovate-therapeutics-and-privately-held-jade-biosciences-have-entered-into-a-definitive-merger-agreement-for-an-all-stock-transaction-the-resulting-entity-will-focus-on-advancing-jades-portfolio-of-biologics-including-jade-001-for-iga-nephropathy

Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the sta...

 aerovate-therapeutics-to-explore-strategic-alternatives-which-may-include-but-are-not-limited-to-an-acquisition-merger-reverse-merger-business-combination-liquidation-or-other-transaction

Aerovate Therapeutics, Inc. (NASDAQ:AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 p...

 evercore-isi-group-downgrades-aerovate-therapeutics-to-in-line-lowers-price-target-to-2

Evercore ISI Group analyst Liisa Bayko downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Outperform to In-Line and lowers ...

 guggenheim-downgrades-aerovate-therapeutics-to-neutral

Guggenheim analyst Vamil Divan downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Neutral.

 wells-fargo-downgrades-aerovate-therapeutics-to-equal-weight-lowers-price-target-to-2

Wells Fargo analyst Tiago Fauth downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Overweight to Equal-Weight and lowers th...

 td-cowen-downgrades-aerovate-therapeutics-to-hold

TD Cowen analyst Joseph Thome downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Hold.

 jefferies-downgrades-aerovate-therapeutics-to-hold-lowers-price-target-to-2

Jefferies analyst Eun Yang downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Hold and lowers the price target from ...

 btig-downgrades-aerovate-therapeutics-to-neutral

BTIG analyst Julian Harrison downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Neutral.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION